Alliance Pharma plc reported sales up by 23% to £170m ($232m) in 2021, thanks to the acquisition of the Amberen menopause supplement and the strong performance of scar-reduction treatment Kelo-Cote. With the group in a strong financial position, it is ready to pursue further M&A in 2022 to strengthen its consumer health offering.
Posting an unaudited trading update for the year, UK-based Alliance said its Consumer Healthcare business had gone from strength to...







